IMMP vs. AKBA, DSGN, EPIX, EBS, ALDX, PYXS, XBIT, OMER, TSVT, and GTHX
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Akebia Therapeutics (AKBA), Design Therapeutics (DSGN), ESSA Pharma (EPIX), Emergent BioSolutions (EBS), Aldeyra Therapeutics (ALDX), Pyxis Oncology (PYXS), XBiotech (XBIT), Omeros (OMER), 2seventy bio (TSVT), and G1 Therapeutics (GTHX). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
In the previous week, Immutep had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Immutep and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.72 beat Immutep's score of 0.40 indicating that Akebia Therapeutics is being referred to more favorably in the news media.
Immutep currently has a consensus price target of $8.50, suggesting a potential upside of 174.19%. Akebia Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 327.35%. Given Akebia Therapeutics' higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Immutep.
2.3% of Immutep shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 3.1% of Immutep shares are owned by insiders. Comparatively, 3.8% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Akebia Therapeutics received 100 more outperform votes than Immutep when rated by MarketBeat users. However, 72.43% of users gave Immutep an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
Immutep has higher earnings, but lower revenue than Akebia Therapeutics.
Immutep has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
Immutep has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -22.99%.
Summary
Immutep and Akebia Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
